Evidence map›Paper›PMID 42252757›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2026

Sulfonated Ionic Covalent Organic Frameworks With Dual-State Activation for Synergistic Photodynamic-Ferroptosis Therapy.

Jiarong Liang, Xiangkun Li, Si Wang, Zhonghui Ma, Fei Kuang, Mengdie Duan, Zhiyi Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiarong LiangSpin-X Institute, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou, China.
Xiangkun LiSpin-X Institute, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou, China.
Si WangSpin-X Institute, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou, China.
Zhonghui MaSpin-X Institute, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou, China.ORCID https://orcid.org/0009-0006-9781-0684
Fei KuangSpin-X Institute, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou, China.
Mengdie DuanSpin-X Institute, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou, China.
Zhiyi WangSchool of Materials, Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.

Funding

National Key Research and Development Program of China 2023YFB3507003National Natural Science Foundation of China 22377026Shenzhen Science and Technology Program JCYJ20250604175505007The Medicine-Engineering Convergence Seed Fund (2025) at Sun Yat-sen University.
6 · The paper itself

Abstract

Conventional photocatalysis is fundamentally constrained by the competitive nature of excited-state dynamics, which typically restricts utilization to a single excitonic channel. Consequently, simultaneously harvesting both excitons to maximize reactive oxygen species (ROS) generation remains a formidable challenge in cancer theragnostic. Herein, an ionic engineering strategy is developed to overcome this excitonic bottleneck by constructing sulfonated covalent organic frameworks (BD-SO

Indexed as

Metal-Organic FrameworksPhotochemotherapyAnimalsCell Line, TumorHumansIonsReactive Oxygen SpeciesSinglet OxygenIonsMetal-Organic FrameworksReactive Oxygen SpeciesSinglet Oxygencovalent organic frameworksDexter energy transferdual‐state activationferroptosisionic sulfonationphotodynamic therapy

Identifiers

PMID42252757
PMCPMC13432674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.